GENEVA--(BUSINESS WIRE)--Regulatory News: GeNeuro (Euronext Paris: CH0308403085 - GNRO), a biopharmaceutical company focused on stopping causal factors driving the progression of neurodegenerative and ...

Back in 2021, at the height of the pandemic, scientists at Pfizer revealed the development of a novel antiviral molecule, designed to hinder the SARS-CoV-2 virus’s ability to replicate. Clinical ...

Late-stage trial data suggest that a new COVID-flu vaccine offers good protection against both infections, but experts expect the shot's approval may be delayed. When you purchase through links on our ...

More than two years after the World Health Organization (WHO) declared an end to the emergency phase of the Covid-19 pandemic ...

WHO said the decision builds on earlier emergency approvals and reflects the continued need for affordable, fast COVID-19 testing even after the pandemic’s emergency phase.

AIM ImmunoTech Inc. announced progress in its clinical development of Ampligen® (rintatolimod), particularly in addressing critical unmet medical needs in areas like pancreatic cancer and Long-COVID.

Moderna’s next-gen COVID vaccine notched a higher immune response than its licensed counterpart, passing a phase 3 test. No data accompanied the company’s announcement Tuesday, with Moderna saying ...